Generic Name: Lymphoseek ()
Lymphoseek Reviews
For Diagnosis and Investigation "Conducted first exploratory use in June 2013, indication cutaneous melanoma, Breslow/3mm. Tilmanocept was well received by the patient with no local clearance delay, provision <20 min. SLN discovery total <4 min/2 SLN/Path."
More about Lymphoseek (tilmanocept)
- Check interactions
- Compare alternatives
- Reviews (1)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: radiologic conjugating agents
- Breastfeeding
Patient resources
- Lymphoseek drug information
Professional resources
- Lymphoseek prescribing information
Related treatment guides
- Diagnosis and Investigation
